Cytosorbents Corporation
CTSO
$0.59
$0.000.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.06M | 36.98M | 36.11M | 35.33M | 35.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.06M | 36.98M | 36.11M | 35.33M | 35.60M |
| Cost of Revenue | 10.57M | 11.04M | 11.58M | 11.11M | 10.71M |
| Gross Profit | 26.49M | 25.94M | 24.53M | 24.22M | 24.89M |
| SG&A Expenses | 35.62M | 33.96M | 33.71M | 33.09M | 33.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.28M | 50.85M | 52.05M | 51.23M | 52.26M |
| Operating Income | -14.22M | -13.87M | -15.94M | -15.90M | -16.66M |
| Income Before Tax | -8.60M | -12.36M | -11.56M | -17.80M | -22.41M |
| Income Tax Expenses | -401.00K | -2.09M | -1.69M | -1.69M | -1.69M |
| Earnings from Continuing Operations | -8.20 | -10.27 | -9.87 | -16.11 | -20.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.20M | -10.27M | -9.87M | -16.11M | -20.72M |
| EBIT | -14.22M | -13.87M | -15.94M | -15.90M | -16.66M |
| EBITDA | -12.72M | -12.35M | -14.40M | -14.35M | -15.09M |
| EPS Basic | -0.13 | -0.18 | -0.18 | -0.29 | -0.38 |
| Normalized Basic EPS | -0.08 | -0.13 | -0.13 | -0.20 | -0.26 |
| EPS Diluted | -0.13 | -0.18 | -0.18 | -0.29 | -0.38 |
| Normalized Diluted EPS | -0.08 | -0.14 | -0.13 | -0.20 | -0.26 |
| Average Basic Shares Outstanding | 248.90M | 240.81M | 232.51M | 224.21M | 217.91M |
| Average Diluted Shares Outstanding | 253.46M | 245.37M | 237.07M | 224.21M | 217.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |